Goldman Sachs
OMGA

Goldman Sachs’s Omega Therapeutics, Inc. Common Stock OMGA Stock Holding History

Goldman Sachs’s Portfolio OMGA Stock Details OMGA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-190,107
Closed -$394K – 6138
2024
Q2 		$394K Buy
190,107
+168,039
+761% +$396K ﹤0.01% 4958
2024
Q1 		$80.5K Buy
22,068
+9,090
+70% +$34.9K ﹤0.01% 5274
2023
Q4 		$39.1K Sell
12,978
-6,900
-35% -$14K ﹤0.01% 5403
2023
Q3 		$42.7K Buy
19,878
+2,796
+16% +$11.2K ﹤0.01% 5295
2023
Q2 		$95.7K Sell
17,082
-34,240
-67% -$268K ﹤0.01% 5363
2023
Q1 		$309K Buy
51,322
+34,816
+211% +$242K ﹤0.01% 5088
2022
Q4 		$94.2K Sell
16,506
-1,274
-7% -$7.15K ﹤0.01% 5494
2022
Q3 		$96K Sell
17,780
-1,796
-9% -$9.1K ﹤0.01% 5693
2022
Q2 		$74K Sell
19,576
-1,945
-9% -$7.24K ﹤0.01% 5942
2022
Q1 		$134K Buy
21,521
+2,470
+13% +$25.2K ﹤0.01% 6014
2021
Q4 		$216K Buy
+19,051
New +$362K ﹤0.01% 5858

Other funds holding OMGA

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Goldman Sachs's OMGA Position: Q3 2024 in Review

Goldman Sachs sold out of Omega Therapeutics, Inc. Common Stock (OMGA) in Q3 2024, closing a stake of 190,107 shares — an estimated $394K sold.

Goldman Sachs first reported a position in OMGA in Q4 2021 and held it in 11 quarters. The position peaked at $394K in Q2 2024. 54 funds tracked by Wall St. Rank hold OMGA as of Q3 2024.

  • Goldman Sachs reported no remaining Omega Therapeutics, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Goldman Sachs sold 190,107 Omega Therapeutics, Inc. Common Stock shares in Q3 2024, an estimated $394K.
  • Goldman Sachs first reported a position in Omega Therapeutics, Inc. Common Stock in Q4 2021 and held it in 11 quarters.
  • Goldman Sachs's Omega Therapeutics, Inc. Common Stock position peaked at $394K in Q2 2024.
  • 54 funds tracked by Wall St. Rank held Omega Therapeutics, Inc. Common Stock as of Q3 2024.

Based on Goldman Sachs's 13F filing for Q3 2024, filed 14 Nov 2024.